PatientsVille.com Logo


Hepatic Enzyme Increased Medical Research Studies

Up-to-date List of Hepatic Enzyme Increased Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hepatic Enzyme Increased Medical Research Studies

Rank Status Study
1 Unknown  Screening for Liver Fibrosis by Using Non-invasive Methods ( Fibro Scan) in Patients With Elevated Liver Enzymes
Condition: Elevated Liver Enzymes
Intervention: Other: No intervention
Outcome Measure: liver stiffness
2 Recruiting Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
Conditions: Liver Disease;   Steatohepatitis;   HIV
Outcome Measures: Presence of hepatic fibrosis on liver biopsy as measured histologically by stage;   Liver biopsy evidence of hepatic steatosis as measured by degree (0 to 4), character and location;   Liver biopsy evidence of hepatic inflammation by type and severity;   Correlation between histopathologic findings on liver biopsy and clinical, laboratory and radiologic parameters
3 Unknown  Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Condition: Non-Alcoholic Fatty Liver Disease
Interventions: Drug: Fish Oil Supplementation;   Drug: Placebo Supplementation
Outcome Measures: 1. To evaluate whether young adults with obesity related NAFLD will normalize their elevated liver enzyme levels with supplements of fish oil (n-3 FA containing eicosapentanoic acid and decosahexaenoic acid).;   Attenuation of insulin resistance
4 Recruiting Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease
Conditions: Non Alcoholic Fatty Liver Disease;   Steatohepatitis;   Hypertriglyceridemia;   Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions: Dietary Supplement: Lovaza;   Other: Omega diet
Outcome Measure: reduction in hepatic fat fraction
5 Recruiting Pancreatic Stone Protein (PSP) in Pregnant Women
Conditions: Pregnancy;   HELLP Syndrome;   Preterm Premature Rupture of Fetal Membranes;   Preeclampsia
Intervention: Procedure: Blood collection
Outcome Measures: Physiological course of PSP in healthy pregnant women;   Predictive role of PSP in the development of complications during pregnancy
6 Unknown  Dexamethasone Efficacy in HELLP I Syndrome
Condition: HELLP Syndrome
Interventions: Drug: Dexamethasone;   Drug: sterile water
Outcome Measures: Duration of hospitalization;   Recovery time of platelets to more than 100000/mm3;   Recovery of AST, ALT and LDH;   Transfusion of blood products
7 Recruiting Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy
Conditions: Severe Hypoxic Ischemic Encephalopathy;   Moderate Hypoxic Ischemic Encephalopathy
Interventions: Drug: Magnesium Sulphate;   Drug: Placebo
Outcome Measures: Combined outcome of Mortality and Severe Neurodevelopmental Disability;   Persistent Hypotension;   Pulmonary Hemorrhage;   Intracranial Hemorrhage;   Pulmonary Hypertension;   Prolonged Blood Coagulation  time;   Culture Proven sepsis;   Necrotizing enterocolitis;   Cardiac Arrhythmias;   Thrombocytopenia;   Major venous thrombosis;   Renal Failure;   Abnormal liver funcion tests (elevated liver enzymes);   Pneumonia;   Pulmonary air leak syndrome;   Prolonged vs shortened hospital stay;   Neurodevelopment score;   Abnormal aEEG;   Presence of multiple handicaps;   Bayley Psychomotor Development Score less than 70;   Sensorineural hearing loss equal to, or more than, 40 dB;   Epilepsy;   Microcephaly;   Result of EEG or MRI
8 Not yet recruiting Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen
Conditions: Patients With Body Temperature Between 37.8-38.5;   No Sign of Infection;   No Liver and Kidney Problem
Interventions: Drug: Tinospora Crispa-extract Product;   Drug: Acetaminophen;   Other: Placebo
Outcome Measures: Body Temperature;   Number of adverse events: diarrhea, elevated liver enzyme and elevated creatinine
9 Recruiting Intravenous Milk Thistle (Silibinin-Legalon) for Hepatic Failure Induced by Amatoxin/Amanita Mushroom Poisoning
Conditions: Amatoxin Poisoning;   Amanita Poisoning;   Mushroom Poisoning;   Liver Failure
Intervention: Drug: Legalon SIL (Silibinin)
Outcome Measures: prevention of severe morbidity (liver transplantation) and death;   Improvement in presenting abnormalities as evaluated by time to normality for hepatic and renal function tests (AST, ALT, bilirubin, PT/INR, creatinine).;   cutaneous reactions;   sodium;   hemoglobin
10 Not yet recruiting The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)
Condition: Fetal Growth Restriction
Interventions: Drug: Sildenafil;   Drug: Placebo
Outcome Measures: Intact neonatal survival until term age;   Fetal growth velocity assessed by ultrasound: abdominal circumference measurements (AC);   Age-adequate performance on the two-year Bayley scales of infant development (BSID)-III (composite cognitive score and composite motor score);   Co-incidence and severity of the maternal syndrome of pre-eclampsia / HELLP-syndrome (Hemolysis Elevated Liver enzymes Low Platelets)
11 Recruiting Fatty Acids, Genes and Microbiota in Fatty Liver
Conditions: Nonalcoholic Fatty Liver Disease;   Steatosis;   Nonalcoholic Steatohepatitis
Outcome Measures: Hepatic fatty acid composition in total lipids in liver biopsy;   Hepatic  gene expression;   Intestinal microbiota composition;   Lipid peroxides in the liver;   Hepatic  liver antioxidant power;   Hepatic  microRNA expression in the liver;   Intestinal microbiota - specific organisms and groups;   Intestinal microbiome on a genetic level;   Short-chain fatty acids in stool;   Plasma endotoxin
12 Recruiting Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial
Condition: MDS and AML Prior to Allogeneic SCT
Intervention: Other: No intervention and study treatment
Outcome Measures: Description of dynamic changes of LPI prior, during and after conditioning for allo-SCT using standard descriptive parameters (Mean or Median and appropriate confidence intervals);   • Correlation coefficient of Liver iron concentration (LIC) and duration of detectable LPI during and after conditioning;   • Area under the Receiver-Operator-Characteristic (ROC) as well as sensitivity and specificity of specific thresholds of serum ferritin and transfusion history for prediction of LIC;   • Association of serum ferritin and LIC with hematopoietic cell transplantation comorbidity index (HCT-CI);   • Time course of LPI, enhanced labile plasma iron (eLPI), directly chelatable iron (DCI) and hepcidin during allo-SCT;   • Association of detectable LPI or eLPI during conditioning and occurrence of elevated liver enzymes during in hospital treatment course for allo-SCT;   • Cumulative incidence of graft versus host disease (aGvHD) grade 2-4 with respect to serum ferritin >1000 µg/l, transfusion burden >20 units of Red blood cells (RBC), LIC >125 µmol/g, peak value and duration of detectable labile plasma iron above median;   • Cumulative incidence of day 100 non-relapse mortality (NRM) with respect to serum ferritin >1000 µg/l, transfusion burden >20 units of RBC, LIC >125 µmol/g and peak value and duration of detectable labile plasma iron above median;   • Cumulative incidence of infections with respect to serum ferritin >1000 µg/l, transfusion burden >20 parasitized red blood cell (PRBC), LIC >125 µmol/g and peak value and duration of detectable labile plasma iron above median;   • Median change of serum ferritin and LIC 100 days and 1 year after allo-SCT;   • Association between immune profile and iron parameters (serum ferritin >1000 µg/l, transfusion burden >20 units RBC, LIC >90 µmol/g and peak value and duration of detectable labile plasma iron above median
13 Unknown  Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
Conditions: Liver Cirrhosis;   Portal Hypertension.
Interventions: Drug: Simvastatin;   Drug: placebo
Outcome Measures: improvement of the hemodynamic response rate;   Portal hypertension complications.;   Adverse effects
14 Recruiting Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab;   Drug: Randomization to No Panitumumab
Outcome Measures: to determine if panitumumab with Hepatic Arterial Infusion (HAI) in combination with systemic chemotherapy can increase the recurrence free survival (RFS) for colorectal cancer patients with resected liver metastases;   to assess toxicity as per the NCI Common Toxicity Criteria;   to determine survival;   to analyze tumor tissue for predictive biomarkers
15 Recruiting Nottingham Community Liver Biomarkers Cohort
Conditions: Chronic Liver Disease;   Alcohol Use Disorder;   Type 2 Diabetes;   Persistently Elevated ALT;   Obesity
Intervention: Device: Fibrosis Biomarkers
Outcome Measures: Liver and cardiovascular-related mortality;   Liver Cirrhosis;   Cardiovascular Disease;   All-cause mortality
16 Recruiting Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men
Condition: Obesity
Interventions: Drug: Letrozole;   Drug: Placebo
Outcome Measures: cardiac function parameters;   Hepatic function parameters;   glucose metabolism;   weight
17 Not yet recruiting Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients
Conditions: Hepacivirus;   HIV Infections
Interventions: Drug: Pentoxifylline;   Drug: Placebo
Outcome Measures: sustained virologic rate 24 weeks post treatment with IFNalpha 2a/RBV/PTX with genotype 1 chronic HCV infection + HIV infection;   grade of hepatic fibrosis;   rapid virologic response (RVR) and extended rapid virologic response (eRVR) rates
18 Recruiting Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?
Conditions: Osteosarcoma;   Spindle Cell Sarcoma of Bone
Interventions: Drug: Glucarpidase;   Drug: Methotrexate;   Drug: Folinic Acid
Outcome Measures: Estimate of the difference in proportions of patients ready to receive chemotherapy on Day 15 of each chemotherapy cycle comparing standard rescue and glucarpidase+standard rescue;   To investigate whether glucarpidase rescue after high-dose methotrexate reduces the incidence of methotrexate associated adverse effects;   Plasma methotrexate concentration;   Incidence of glucarpidase related adverse effects;   Number of days required in hospital per cycle;   Assessment of quality of life;   Serum anti-glucarpidase IgG levels following glucarpidase administration;   To investigate whether glucarpidase rescue after high-dose methotrexate reduces the severity of methotrexate associated adverse effects;   To investigate whether glucarpidase rescue after high-dose methotrexate reduces the duration of methotrexate associated adverse effects;   Plasma DAMPA concentration;   Total dose of folinic acid rescue required per cycle
19 Recruiting Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
Conditions: Alpha-1-antitrypsin Deficiency;   Liver Cirrhosis
Interventions: Drug: Drug-Carbamazepine (Tegretol XR);   Drug: Carbamazepine (Tegretol XR) Placebo
Outcome Measures: The primary outcome will be to determine the effect of Carbamazepine on hepatic ATZ load.;   For the secondary outcomes we will determine the effect of Carbamazepine treatment on hepatic fibrosis.;   For the secondary outcome we will determine if Carbamazepine treatment reduces the MELD score.
20 Not yet recruiting Effects of Pitavastatin on Insulin Sensitivity and Liver Fat
Conditions: Obesity;   Fatty Liver, Nonalcoholic
Intervention: Drug: pitavastatin
Outcome Measures: Insulin-stimulated glucose uptake;   Liver fat;   alanine aminotransferase (ALT);   aspartate aminotransferase (AST);   hepatic insulin sensitivity;   hemoglobin A1c (HbA1c);   quantitative insulin sensitivity check index (QUICKI)

These studies may lead to new treatments and are adding insight into Hepatic Enzyme Increased etiology and treatment.

A major focus of Hepatic Enzyme Increased research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Hepatic Enzyme Increased